头颈癌以生活质量和毒性为导向的治疗计划优化
本研究纳入30例接受根治性放疗的头颈癌患者,评估半自动生活质量加权NTCP引导VMAT计划优化的可行性。结果显示该计划临床可接受、靶区覆盖不劣于常规计划,优先保护高影响毒性相关危及器官,预测生活质量在6至24个月均改善(p<0.001)。
要点
- 生活质量加权NTCP引导VMAT计划临床可接受且靶区覆盖不劣于常规计划。
- 该计划优先保护对生活质量影响最大的毒性和症状相关危及器官。
- 预测生活质量在6、12、18、24个月分别平均改善0.7、0.9、1.0、1.1分(0-100量表,p<0.001)。
核心结论
- 半自动生活质量加权NTCP引导VMAT计划优化在头颈癌中可行,优先保护高影响毒性相关危及器官,较常规VMAT系统性改善预测生活质量。
研究设计与样本
- 研究纳入30例接受根治性放疗的头颈癌患者,基于80个多变量NTCP模型(涵盖20种常见毒性和症状、4个时间点)直接优化生活质量加权NTCP引导VMAT计划,并与临床常规VMAT计划比较。
主要发现
- 生活质量加权NTCP引导VMAT计划临床可接受,靶区覆盖与临床计划同等充分,但优先保护对生活质量影响最高的毒性和症状相关危及器官。
- 6个月时吞咽困难NTCP降低(≥2级-6.1%,≥3级-7.6%),中重度疲劳/言语问题/声嘶分别降低0.7%/1.5%/2.5%。
- 同时唾液功能相关毒性平均NTCP增加+0.4%至+5.7%。
- 该计划制作时间更短、对治疗计划师经验依赖更小且结果更一致。
- 预测生活质量在6、12、18、24个月分别平均改善0.7、0.9、1.0、1.1分(0-100量表,p<0.001)。
临床怎么用
- 可将生活质量加权NTCP引导的半自动VMAT计划优化用于头颈癌放疗,以优先保护高影响毒性相关危及器官并提升预测生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the feasibility of semi-automatic Quality of Life (QOL)-weighted normal tissue complication probability (NTCP)-guided VMAT treatment plan optimisation in head and neck cancer (HNC) and compare predicted QOL to that obtained with conventional treatment. MATERIALS AND METHODS: This study included 30 HNC patients who were treated with definitive radiotherapy. QOL-weighted NTCP-guided VMAT plans were optimised directly on 80 multivariable NTCP models of 20 common toxicities and symptoms on 4 different time points (6, 12, 18 and 24 months after radiotherapy) and each NTCP model was weighted relative to its impact on QOL. Planning results, NTCP and predicted QOL were compared with the clinical conventional VMAT plans. RESULTS: QOL-weighted NTCP-guided VMAT plans were clinically acceptable, had target coverage equally adequate as the clinical plans, but prioritised sparing of organs at risk (OAR) related to toxicities and symptoms that had the highest impact on QOL. NTCP was reduced for, e.g., dysphagia (-6.1% for ≥grade 2/-7.6% for ≥grade 3) and moderate-to-severe fatigue/speech problems/hoarseness (-0.7%/-1.5%/-2.5%) at 6 months, respectively. Concurrently, the average NTCP of toxicities related to salivary function increased with +0.4% to +5.7%. QOL-weighted NTCP-guided plans were produced in less time, were less dependent on the treatment planner experience and yielded more consistent results. The average predicted QOL improved by 0.7, 0.9, 1.0, and 1.1 points on a 0-100 scale (p < 0.001) at 6, 12, 18, and 24 months, respectively, compared to the clinical plans. CONCLUSION: Semi-automatic QOL-weighted NTCP-guided VMAT treatment plan optimisation is feasible. It prioritised sparing of OARs related to high-impact toxicities and symptoms and resulted in a systematic improvement of predicted QOL compared to conventional VMAT.
引用
- van der Laan HP, van der Schaaf A, Van den Bosch L, et al. Quality of life and toxicity guided treatment plan optimisation for head and neck cancer. Radiother Oncol. 2021. PMID: 34237344. doi:10.1016/j.radonc.2021.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。